Evidence map›Paper›PMID 41454472›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Toward a global research agenda for preventing multiple sclerosis.

Ruth Ann Marrie, Ruth Dobson, Sergio E Baranzini, Marco Salvetti, Caroline Bailey, Bruce Bebo, Benjamin Davis, Rohan Greenland, Jen Lyden, Fiona Mckay and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Ruth Ann MarrieDepartments of Medicine and Community Health and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada; Department of Medicine, Nova Scotia Health Authority, Halifax, NS, Canada.ORCID 0000-0002-1855-5595
Ruth DobsonCentre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University London, London, UK.ORCID 0000-0002-2993-585X
Sergio E BaranziniWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-0067-194X
Marco SalvettiDepartment of Neurosciences, Mental Health and Sensory Organs, University of Rome La Sapienza, Rome, Italy; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy.ORCID 0000-0002-0501-8803
Caroline BaileyMcKing Consulting Corporation, Chamblee, GA, USA.
Bruce BeboAdvocacy, Services and Research, National Multiple Sclerosis Society, New York, NY, USA.ORCID 0000-0003-0941-9169
Benjamin DavisMS Canada, Toronto, ON, Canada.
Rohan GreenlandMS Australia, Summer Hill, NSW, Australia.
Jen LydenRaleigh, Independent Researcher, NC, USA.
Fiona MckayMS Australia, Summer Hill, NSW, Australia.
Julia MorahanMS Australia, Summer Hill, NSW, Australia.
Julie PetrinMS Canada, Toronto, ON, Canada.ORCID 0000-0003-4852-0286
Pamela ValentineMS Canada, Toronto, ON, Canada.
Bruce TaylorMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.
participants in the “Global MS Prevention Workshop”

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConsiderable progress has been made in understanding genetic and environmental risk factors for multiple sclerosis (MS), yet we still cannot prevent MS.

objectivesTo drive progress in primary and secondary prevention of MS by developing a comprehensive research agenda based on current knowledge.

methodsA global workshop convened people with lived experience, clinicians, researchers, and policymakers with expertise in MS, other chronic diseases, epidemiology, clinical trials, genomics, immunology, virology, behavioral science, and public health to develop pathways to advance the MS prevention agenda.

resultsRegarding primary prevention, workshop participants recommended acting on known modifiable risk factors; identifying novel etiological factors and determining how they lead to disease; and building coalitions including organizations with shared interests. Regarding secondary prevention, workshop participants recommended identifying biomarkers relevant from initial immune dysregulation through to initial clinical presentation, linking biomarkers to long-term MS outcomes, developing cost-effective screening tools for MS and point-of-care testing, and developing prodromal criteria for MS that could be implemented clinically. Communication and evaluation frameworks, adoption of an implementation mind-set, and engagement of public health were highlighted as key supporting elements.

conclusionThis workshop sets the stage for developing a global prevention agenda for MS.

Indexed as

Biomedical ResearchMultiple SclerosisPrimary PreventionSecondary PreventionBiomarkersGlobal HealthHumansRisk FactorsBiomarkersMultiple sclerosispreventionprodromeresearch agendarisk factors

Identifiers

PMID41454472
PMCPMC12916883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.